Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 433-441 , August 2009

The contribution of incretin hormones to the pathogenesis of type 2 diabetes

  • Juris J. Meier, MD (Professor, Doctor)

      Affiliations

    • Corresponding Author InformationTel.: +49 234 509 2711; Fax: +49 234 509 2713.

References 

  1. Meier JJ, Butler PC. Insulin secretion. In:  DeGroot LJ,  Jameson JL editor. Endocrinology. 5th edn.. Philadelphia: Elsevier Saunders; 2005;p. 961–973
  2. Horowitz M, Edelbroek MA, Wishart JM, et al. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857–862
  3. Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002;19:177–194
  4. Meier JJ, Kemmeries G, Holst JJ, et al. Erythromycin antagonises the deceleration of gastric emptying by glucagon-like peptide 1 (GLP-1) and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005;54:2212–2218
  5. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Digestive Diseases and Sciences. 1985;30(1):1–9
  6. Hanefeld M. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. Journal of Diabetes Complications. 1998;12(4):228–237
  7. Nauck MA, Siemsglüß J, Ørskov C, et al. Release of glucagon-like peptide 1 (GLP-1 [7–36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Zeitschrift für Gastroenterologie. 1996;34:159–166
  8. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. The Journal of Physiology. 1970;209:57–64
  9. Brown JC, Pederson RA, Jorpes E, et al. Preparation of highly active enterogastrone. Canadian Journal of Physiology and Pharmacology. 1969;47:113–114
  10. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology. 1994;107:1848–1855
  11. Schmidt WE. The intestine, an endocrine organ. Digestion. 1997;58(Suppl. 1):56–58
  12. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75–85
  13. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia. 1985;28:565–573
  14. Nauck MA, Bartels E, Ørskov C, et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. The Journal of Clinical Endocrinology and Metabolism. 1993;76:912–917
  15. Ørskov C, Rabenh¢j L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes. 1994;43:535–539
  16. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3717–3723
  17. Vilsbøll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613
  18. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678–687[Epub 2007 Dec 5]
  19. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123:2009–2013
  20. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences. 1993;38:665–673
  21. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2719–2725
  22. Meier JJ, Goetze O, Anstipp J, et al. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. American Journal of Physiology. Endocrinology and Metabolism. 2004;286:E621–E625
  23. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46:798–801
  24. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. The Journal of Clinical Investigation. 1967;46:1954–1962
  25. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. The Journal of Clinical Endocrinology and Metabolism. 1986;63:492–498
  26. Meier JJ, Deacon CF, Schmidt WE, et al. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia. 2007;50:806–813
  27. Knop FK, Vilsboll T, Madsbad S, et al. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007;50(4):797–805[Epub 2007 Jan 16]
  28. DeFronzo RA. The triumvirate: ß-cell, muscle and liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687
  29. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37:1593–1607
  30. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  31. Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation. 1984;74:1318–1328
  32. Pfeifer MA, Halter JB, Porte D. Insulin secretion in diabetes mellitus. American Journal of Medicine. 1981;70(3):579–588
  33. Muller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. The New England Journal of Medicine. 1970;283(3):109–115
  34. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–54
  35. Crockett SE, Mazzaferri EL, Cataland S. Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus. Diabetes. 1976;25(10):931–935
  36. Ross SA, Brown JC, Dupré J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes. 1977;26:525–529
  37. Ebert R, Creutzfeldt W. Hypo- and hypersecretion of GIP in maturity-onset diabetics. [abstract] Diabetologia. 1980;19:271–272
  38. Amland PF, Jorde R, Aanderup S, et al. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scandinavian Journal of Gastroenterology. 1985;20:315–320
  39. Nauck MA, Heimesaat MM, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation. 1993;91:301–307
  40. Meier JJ, Hücking K, Holst JJ, et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 2001;50:2497–2504
  41. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes and healthy control subjects. Diabetes. 2004;53(Suppl. 3):S220–S224
  42. Vilsbøll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–1119
  43. Meier JJ, Nauck MA, Siepmann N, et al. Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism. 2003;52:1579–1585
  44. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340–1348[Epub 2007 Dec 27]
  45. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology. 2006;155(3):485–493
  46. Ørskov C, Jeppesen J, Madsbad S, et al. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. The Journal of Clinical Investigation. 1991;87:415–423
  47. Meier JJ, Nauck MA. Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?. Nature Clinical Practice. Endocrinology & Metabolism. 2008;4(11):606–607[Epub 2008 Aug 26]
  48. Kjems LL, Holst JJ, Vølund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380–386
  49. Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744
  50. Rachman J, Gribble FM, Levy JC, et al. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205–211
  51. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effects of glucagon-like peptide-1 (7–36) amide on ad libidum energy intake in humans. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4382–4389
  52. Köbberling J, Tillil H, Lorenz H-J. Genetics of type 2A- and type 2B-Diabetes mellitus. [Abstract] Diabetes Research and Clinical Practice. 1985;1(Suppl. 1):311
  53. Nauck MA, El-Ouaghlidi A, Gabrys B, et al. Secretion of Incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides. 2004;122:209–217
  54. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53(Suppl. 3):S190–S196
  55. Meier JJ, Nauck MA, Siepmann N, et al. Insulin secretion following a bolus injection of Gastric Inhibitory Polypeptide (GIP) in first-degree relatives of type 2 diabetic patients and healthy control subjects. [abstract] Diabetes. 2002;51(Suppl. 2):A580
  56. Meier JJ, Gallwitz B, Askenas M, et al. Secretion of incretin hormones and the insulinotropic effect of Gastric Inhibitory Polypeptide (GIP) in women with a history of gestational diabetes. Diabetologia. 2005;48:1872–1881
  57. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. The Journal of Clinical Endocrinology and Metabolism. 2003;88(10):4897–4903
  58. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes - cause or consequence of the diabetic state?. Diabetes. 2007;18:18
  59. Hojberg PV, Vilsboll T, Zander M, et al. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with type 2 diabetes. Diabetic Medicine. 2008;25(11):1268–1275
  60. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2008;27:27
  61. Lynn PC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011
  62. Turner RC, McCarthy ST, Holman RR, et al. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. British Medical Journal. 1976;1(6020):1252–1254
  63. Laedtke T, Kjems L, Porksen N, et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. American Journal of Physiology. Endocrinology and Metabolism. 2000;279(3):E520–E528
  64. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995;18(6):843–851
  65. Lynn FC, Thompson SA, Pospisilik JA, et al. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB Journal. 2003;17(1):91–93
  66. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56(6):1551–1558[Epub 2007 Mar 14]
  67. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target?. Diabetologia. 2008;51(5):703–713[Epub 2008 Mar 4]

PII: S1521-690X(09)00026-8

doi: 10.1016/j.beem.2009.03.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 433-441 , August 2009

Article Tools

* Image Usage & Resolution